Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2176 to 2190 of 9087 results

  1. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]

    Awaiting development Reference number: GID-TA11358 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]

    Awaiting development Reference number: GID-TA10993 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Aprocitentan for treating resistant hypertension [ID6681]

    Awaiting development Reference number: GID-TA11459 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297]

    Technology appraisal Reference number: TA714 Published:  14 July 2021

    Technology appraisal guidance
    In development

  5. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development Reference number: GID-TA11422 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  6. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date:  05 August 2026

    Technology appraisal guidance
    In development

  7. Artificial intelligence (AI) technologies to help detect prostate cancer on MRI

    In development Reference number: GID-HTG10879 Expected publication date:  12 November 2026

    HealthTech guidance
    In development

  8. Asciminib for untreated Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase

    Awaiting development Reference number: GID-TA12455 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Osimertinib for adjuvant treatment of EGFR mutation-positive stage 1A2 or 1A3 non-small-cell lung cancer after complete tumour resection

    Awaiting development Reference number: GID-TA12457 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Vonaprument for treating geographic atrophy caused by age-related macular degeneration

    Awaiting development Reference number: GID-TA12454 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. PillCam COLON 2 for investigation of the colon through direct visualisation

    Deferred Reference number: GID-HTG10900

    HealthTech guidance
    Deferred

  12. Tanruprubart for treating Guillain–Barre syndrome in people 12 years and over

    Awaiting development Reference number: GID-TA12453 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Surgical mesh for treatment of primary ventral hernias

    In development Reference number: GID-HTG10876 Expected publication date:  24 June 2027

    HealthTech guidance
    In development

  14. Digital technologies delivering CBT for insomnia in adults

    In development Reference number: GID-HTG10888 Expected publication date:  06 January 2027

    HealthTech guidance
    In development

  15. Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

    Awaiting development Reference number: GID-TA11835 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development